
Benitec Biopharma Inc.: financial statements
Price
$7.92
November 20, 2026Market cap $392M
What Ploutos Investor adds for Benitec Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from FY2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | FY2024 | FY2025 | FY2026 | Average a year |
|---|---|---|---|---|
| Revenue | $0 | – | – | |
| Operating income | -$22M | -$42M | -$51M | |
| Net income | -$22M | -$38M | -$46M | |
| Earnings per share | -$1.22 | -$1.05 | -$0.98 | |
| Earnings per share, basic | -$1.22 | -$1.05 | -$0.98 |
Financial statements
BNTC's revenue, profits and cash flows from FY2019 to FY2023, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- Royalty
- Service
- License
- FY2019: Royalty $183.0K, Service $1.1M, License $10M
- FY2020: Royalty $93.0K, Service $4.0K, License –
| Product | FY2019 | FY2020 | Share FY2020 |
|---|---|---|---|
| Royalty | $183.0K | $93.0K | 96% |
| Service | $1.1M | $4.0K | 4.1% |
From the XBRL of 7 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Jun 30, 2026Operating leases
$762.0K
Finance leases
–
The liability is the present value of the rent still to pay, at June 30, 2026. It is not counted in the ladder's debt. The filing
Lease liability by year
Leases
BNTC's leases from FY2020 to FY2023, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the statutory to the effective tax rate, FY2026
Jun 30, 2026Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Prior-year adjustments
+0.5 pts
Change in valuation allowance
-11.2 pts
Executive pay deduction limit
-9.0 pts
Share-based compensation
-1.4 pts
Smaller lines (2)
+0.0 pts
Effective rate
0.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
Effective tax rate by year
The tax rate BNTC paid on its profit, from FY2019 to FY2023, 5 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Benitec Biopharma's filings show?
These are Benitec Biopharma's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does BNTC have?
On June 30, 2026 Benitec Biopharma had total assets of $183M, debt of – and shareholders' equity of $177M.
How much free cash flow does BNTC have?
In fiscal FY2026 Benitec Biopharma had cash from operations of -$17M and spent $105.0K on capital expenditure, leaving -$17M of free cash flow.
Where are the figures from?
From Benitec Biopharma Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.